sb 202190 has been researched along with Carcinoma, Medullary in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Liu, Z | 1 |
Falola, J | 1 |
Zhu, X | 1 |
Gu, Y | 1 |
Kim, LT | 1 |
Sarosi, GA | 1 |
Anthony, T | 1 |
Nwariaku, FE | 1 |
1 other study available for sb 202190 and Carcinoma, Medullary
Article | Year |
---|---|
Antiproliferative effects of Src inhibition on medullary thyroid cancer.
Topics: Apoptosis; Carcinoma, Medullary; Cell Division; Cell Line, Tumor; CSK Tyrosine-Protein Kinase; Enzym | 2004 |